linjc16/ctgov huggingface dataset:
Effects of The Effects of Dietary Oils on Fasting Lipoprotein Lipids

Study Overview
=================
Brief Summary
-----------------
The objectives of this clinical trial are to assess the effects of dietary oils on blood lipids and other aspects of the fasting lipoprotein profile in healthy men and women with elevated cholesterol

Official Title
-----------------
A Randomized Double Blind Controlled Crossover Trial to Assess the Effects of Dietary Oils on Fasting Lipoprotein Lipids

Conditions
-----------------
Hypercholesterolemia

Intervention / Treatment
-----------------
* Other: Corn oil
* Other: Olive oil


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Fasting LDL-C level equal to or greater than 130 mg/dL and less than 200 mg/dL at visit 1 Fasting triglycerides less than or equal to 350 mg/dL at visit 1 Exclusion Criteria: Has coronary heart disease or coronary heart disease risk risk equivalent, such as diabetes, atherosclerosis, etc Taking lipid medications intended to alter the lipids profile, including but not limited to statins, bile acid sequestrants, etc. Uncontrolled hypertension (systolic greater than or equal to 160 mm Hg or diastolic greater than or equal to 100 mm Hg)

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 74 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Corn oil/olive oil<br>Corn oil 56 g per day for 21 days followed by olive oil 56 g for 21 days | Other: Corn oil<br>* corn oil 56 g/day for 21 days<br>Other: Olive oil<br>* olive oil 56 g /day for 21 days<br>|
| Experimental: Olive Oil/Corn Oil<br>olive oil, 56g per day for 21 days followed by corn oil, 56 g for 21 days | Other: Corn oil<br>* corn oil 56 g/day for 21 days<br>Other: Olive oil<br>* olive oil 56 g /day for 21 days<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Low Density Lipoprotein cholesterol |  | Time Frame: baseline (average days -7 and 0) and the end of each treatment period [Treatment 1 averages of days 19 and 21and Treatment II (average of days 19 and 21)]: patients are followed for an average of 11 weeks | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| total cholesterol |  | baseline (average of days -7 and 0) and the end of each treatment period [Treatment I average of days 19 and 21) and treatment II (average of days 19 and 21)]: patients are followed for an average of 11 weeks | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
cholesterol,LDL, vegetable oils, heart diseases
A Comparative Study of the Performance of a New Type Non-contact Patient Monitor

Study Overview
=================
Brief Summary
-----------------
To verify the accuracy and reliability of the ultra wideband (UWB) non-contact breath rate and heart rate monitor, ICU bedside monitor is used as the gold standard.

Detailed Description
-----------------
In this study, 50 volunteer patients are tested on the UWB non-contact breath rate and heart rate monitor. The testing time length for each patient is set to two hours. Subject is not to be restrained and nurse is allowed to take care the subject while testing. The breath rate and heart rate data will be analyzed for their accuracy against the MP60 (Philips) bedside monitor.

Official Title
-----------------
Clinical Test of Ultra-Wideband Non-contact Heart Rate and Breath Rate Monitor

Conditions
-----------------
Indication for Modification of Patient's Cardiopulmonary Status

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: conscious adult, > 18 years old Exclusion Criteria: non-conscious, pregnant women, epilepsy patients, patients with heart pacemaker or ACIDS, patients on respirator

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
UWB, non-contact, patient monitor
Achieving Hybrid Monovision By Paring Monofocal And EDOF Lens Technology

Study Overview
=================
Brief Summary
-----------------
Modern day cataract surgery isn't just a rehabilitative procedure anymore but rather aims at improving a patient's quality of life by reducing the need for spectacles in everyday life to a minimum. One way of achieving this goal is by using different lens technologies, such as a monofocal lens paired a lens with EDOF technology, as EDOF lenses provide an enhanced depth of focus by creating a single elongated focal point. As this mix-and-match is well established, the aim of this study is to compare the monofocal lens cohort to the EDOF lens cohort and evaluate visual acuity and patient satisfaction.

Official Title
-----------------
The Implantation Of Monofocal And Premium IOL Models - A Registry Study At The Kepler University Hospital

Conditions
-----------------
Cataract Senile

Intervention / Treatment
-----------------
* Procedure: IOL Implantation:EDOF lens
* Procedure: IOL Implantation: Monofocal lens


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patient age between 21-99 years signed consent form senile cataract LOCS III grading Cataract surgery with monofocal or premium lens implantation Exclusion Criteria: missing signed consent form macular pathologies corneal pathologies irregular astigmatism pregnancy

Ages Eligible for Study
-----------------
Minimum Age: 21 Years
Maximum Age: 99 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| EDOF<br>Eye after EDOF lens Implantation | Procedure: IOL Implantation:EDOF lens<br>* A EDOF lens is implanted in the dominant eye<br>|
| Monofocal<br>Eye after Monofocal lens Implantation | Procedure: IOL Implantation: Monofocal lens<br>* A monofocal lens is implanted in the non dominant eye.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| uncorrected distance visual acuity | Percentage of patients with uncorrected distance visual acuity of logMAR >0.1 | 24 months | 
| uncorrected intermediate distance visual acuity | Percentage of patients with uncorrected intermediate distance visual acuity of logMAR >0.2 | 24 months | 
| uncorrected near visual acuity | Percentage of patients with uncorrected near visual acuity of logMAR >0.2 | 24 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Dysphotopsia | Quality of Vision questionnaire | 24 months | 
| PRISQ-Questionnaire | questionnaire rating spectacle independency | 24 months | 
| Patient Satisfaction | Catquest 9-SF-Questionnaire | 24 months |
Is There a Relationship Between Stress Tolerance and Analgesic Consumption in Obese Patients?

Study Overview
=================
Brief Summary
-----------------
Preoperative anxiety level of patients affects postoperative analgesic consumption. However, there were no studies that showed a relationship between the level of stress tolerance and analgesic consumption in the literature. In this study, investigators wanted to investigate the effect of stress tolerance on analgesic consumption of patient.

Detailed Description
-----------------
After approval, patients enrolled in the study is invited to complete the Pain Catastrophizing Scale questionnaire, Distress Tolerance Scale and Beck anxiety scale.After surgery, VAS scores of the patients will be evaluated (in the recovery room, 2,6,12 and 24 hours). and patients with VAS> 3 will receive 2 mg of morphine.The relationship between total analgesic consumption and the stress tolerance will be evaluated.The study will be performed with 69 sleeve gastrectomy patients(BMI>30).

Official Title
-----------------
Is There a Relationship Between Stress Tolerance and Analgesic Consumption in Obese Patients?

Conditions
-----------------
Distress Tolerance

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Between 18 and 60 years Planned to sleeve gastrectomy An American Society of Anesthesiologists score of 1 or 2 BMI>30 Exclusion Criteria: Psychiatric diseases Rejected to participation

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 60 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The effect of patient anxiety tolerance on analgesic consumption | Assessment of analgesic consumption according to the patient's anxiety. tolerance.The distress tolerance scale will be used for this. | one time in four months |
Psychiatric Problems in Chronic Skin Diseases

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to investigate the prevalence of depression, anxiety, and sleep problems in patients with chronic skin diseases in dermatology clinics at the University of Wisconsin Hospital and Clinics.

Official Title
-----------------
Quality of Life, Emotional and Sleep Problems in Chronic Skin Diseases

Conditions
-----------------
Psoriasis, Acne, Vitiligo, Atopic Dermatitis, Pruritic Dermatitis

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Subjects suffering from a chronic skin condition that has lasted over six months Exclusion Criteria: -

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
GIP Effects at Insulin Induced Hypoglycemia in Patients With Type 2 Diabetes

Study Overview
=================
Brief Summary
-----------------
Investigation of GIP effects at fasting and hypoglycemia

Official Title
-----------------
Effects of Glucose-dependent Insulinotropic Polypeptide at Insulin Induced Hypoglycemia in Patients With Type 2 Diabetes

Conditions
-----------------
Type 2 Diabetes Mellitus

Intervention / Treatment
-----------------
* Other: Glucose-dependent Insulinotropic polypeptide
* Other: saline


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Caucasians 18 years or older with Type 2 diabetes (WHO criteria) Exclusion Criteria: HbA1c >9 % Liver disease (ALAT/ASAT >2 x upper normal limit) Diabetic nephropathy (s-creatinine >130 µM or albuminuria) Proliferative diabetic retinopathy (anamnestic) Severe arteriosclerosis or heart failure (NYHA group III og IV) Anemia treatment with medication not applicable to pause for 12 hours Fasting plasma glucose >15 mM on screening day.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 70 Years

Sexes Eligible for Study
-----------------
Male

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Basic Science
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Triple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: hyperglycemia<br> | Other: Glucose-dependent Insulinotropic polypeptide<br>* infusion 4 pmol x kg x min first 15 min, thereafter 2 pmol x kg x min<br>Other: saline<br> <br> |
| Experimental: fasting glycemia<br> | Other: Glucose-dependent Insulinotropic polypeptide<br>* infusion 4 pmol x kg x min first 15 min, thereafter 2 pmol x kg x min<br>Other: saline<br> <br> |
| Experimental: hypoglycemia<br> | Other: Glucose-dependent Insulinotropic polypeptide<br>* infusion 4 pmol x kg x min first 15 min, thereafter 2 pmol x kg x min<br>Other: saline<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| glucagon/insulin(c-peptide) absolute, incremental and area under curve values |  | approx. 15 minutes intervals, time 0 to 120 min | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| plasma gut hormones and nutrients |  | approx. 15 minutes intervals, time 0 to 120 min |
Pharmacological Treatment of Children and Adolescents With Severe Mood Dysregulation

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to investigate whether Risperidone is effective in children and adolescents with severe mood dysregulation.

Detailed Description
-----------------
Severe Mood Dysregulation(SMD) is a new construct in children and adolescents characterized by persistent and non episodic irritability, hyperarousal and emotional reactivity. This is an open label trial using Risperidone in children and adolescents( 7-17 years old) diagnosed with SMD. We hypothesized that Risperidone would improve externalizing symptoms as well as depressive and/or maniac symptomatology. We also consider the effect of the pharmacological intervention in the co-morbid disorders especially ADHD.

Official Title
-----------------
Pharmacological Treatment of Children and Adolescents With Severe Mood Dysregulation. An Open Trial With Risperidone.

Conditions
-----------------
Severe Mood Dysregulation

Intervention / Treatment
-----------------
* Drug: Risperidone


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Diagnose of Severe Mood Dysregulation 7-17 years IQ > 70 Exclusion Criteria: Bipolar disorder IQ<70 Psychosis

Ages Eligible for Study
-----------------
Minimum Age: 7 Years
Maximum Age: 17 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: Single


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Risperidone|0,5-4 mg/day for 8 weeks (twice a day)|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| We use as the primary outcome the subscale of irritability of the Aberrant Checklist Behavior which measures the intensity of irritability, temper tantruns and hyperarousal symptoms |  | 11/2010 | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Risperidone, Severe mood dysregulation, bipolar, children
Duration of Platelet Inhibition by Aspirin

Study Overview
=================
Brief Summary
-----------------
The well established importance of regular aspirin administration stands on firm grounds, as large meta-analyses have shown this therapy to significantly reduce the risk of death. However, not all patients benefit of aspirin administration to the same extent, thus high-lighting a sub-population of patients with inadequate platelet response to ASA. The mechanisms underlying reduced ASA efficacy remain elusive. A recent report has suggested that platelets, long believed to be incapable of de novo protein synthesis, may retain their ability to form the cyclooxygenase enzyme, once it has been inactivated by aspirin. This may explain the inefficacy of the drug to induce sustained platelet inhibition in certain patients. The current study aims to evaluate, in patients suffering from stable coronary artery disease, the stability of platelet inhibition by aspirin during the normal once daily dosing regimen.

Official Title
-----------------
Evaluation of Duration of Platelet Inhibition by Aspirin in a Standard 24-hour Interval Dosing Regimen

Conditions
-----------------
Coronary Artery Disease

Intervention / Treatment
-----------------
* Other: Platelet aggregation


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients suffering from stable CAD, on chronic ASA therapy Patients willing to participate in the study and to sign the informed consent form Exclusion Criteria: Acute coronary syndrome or revascularization in the last 3 months prior to enrolment Concurrent ingestion of nonsteroidal anti-inflammatory drugs (NSAIDs, including COX-2 selective anti-inflammatory drugs), clopidogrel, ticlopidine, dipyridamole, warfarin or acenocoumarol Frequent use (more than once a week) of non-prescription NSAIDs or drugs containing ASA in the 10 days preceding enrolment Major surgical procedure within 1 month before enrolment Hemorrhagic diathesis or known platelet dysfunction Platelet count outside the 100 to 450 x109/L range for technical reasons Hematocrit < 25% or haemoglobin < 100 g/L Patient undergoing dialysis for chronic renal failure Patient found to be ASA resistant

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 90 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| 1<br>Patients suffering from stable CAD, on chronic ASA therapy | Other: Platelet aggregation<br>* Platelet aggregation TxA2 formation<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Platelet aggregation TxA2 formation |  |  | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
platelet aggregation, aspirin
Tailoring Screening, Brief Intervention, and Referral to Treatment for Medical ICU Survivors

Study Overview
=================
Brief Summary
-----------------
Unhealthy alcohol use is present in up to 38% of the 4 million patients admitted to an American intensive care unit (ICU) each year in the US. Despite the high prevalence of unhealthy alcohol use in ICU survivors, routine interventions targeted at reducing alcohol consumption, alcohol-related consequences, and illness related to alcohol are not currently part of the multidisciplinary approach to critical care. Although screening, brief intervention, and referral to treatment (SBIRT) has been described in several healthcare settings, it fails to address common characteristics of medical ICU survivors including high rates of alcohol use disorders, cognitive dysfunction, psychiatric comorbidities, and intimate involvement of friends and family. This study uses a qualitative approach to further understand the needs of medical ICU survivors with unhealthy alcohol use. The investigators hypothesize that there are common, modifiable barriers to improving alcohol-related outcomes

Official Title
-----------------
Tailoring Screening, Brief Intervention, and Referral to Treatment for Medical Intensive Care Unit Survivors

Conditions
-----------------
Unhealthy Alcohol Use, Alcohol Use Disorders

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: 18 years or older admitted to the medical ICU resolution of critical illness resolution of delirium/agitation AUDIT score 8 or greater for men, 5 or greater for women Exclusion Criteria: unable to provide informed consent prisoner Unable to speak or write in English Pregnant

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 100 Years

Sexes Eligible for Study
-----------------
Male

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change in alcohol use | Change in alcohol use as assessed using a Semi-structured qualitative interview | 3 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
SBIRT, Unhealthy alcohol use, ICU survivors, Alcohol use disorder, Screening, brief intervention, and referral to treatment